Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026Cas…